- Published: October 2, 2022
- Updated: October 2, 2022
- University / College: Swansea University
- Language: English
- Downloads: 26
A commentary on
Ben-Izhak, O., Akrish, S., Gan, S., and Nagler, R. M. (2009). Skp2 and salivary cancer. Cancer Biol. Ther. 8, 153–158.
Chang, H. C., Chang, F. R., Wang, Y. C., Pan, M. R., Hung, W. C., and Wu, Y. C. (2007). A bioactive with anolide tubocapsanolide A inhibits proliferation of human lung cancer cells via repressing Skp2 expression. Mol. Cancer Ther. 6, 1572–1578.
Hung, W. C., Tseng, W. L., Shiea, J., and Chang, H. C. (2010). Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. Cancer Lett. 288, 156–161.
Jiang, J., Pan, Y., Regan, K. M., Wu, C., Zhang, X., Tindall, D. J., et al. (2012). Androgens repress expression of the F-box protein Skp2 via p107 dependent and independent mechanisms in LNCaP prostate cancer cells. Prostate 72, 225–232.
Lu, M., Zhao, Y., Xu, F., Wang, Y., Xiang, J., and Chen, D. (2012). The expression and prognosis of FOXO3a and Skp2 in human ovarian cancer. Med. Oncol . PMID: 22714061. [Epub ahead of print].
Schuler, S., Diersch, S., Hamacher, R., Schmid, R. M., Saur, D., and Schneider, G. (2011). SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis. Int. J. Oncol. 38, 219–225.
Shi, P., Zhang, Y., Tong, X., Yang, Y., and Shao, Z. (2011). Dihydrotestosterone induces p27 degradation via direct binding with SKP2 in ovarian and breast cancer. Int. J. Mol. Med. 28, 109–114.
Tang, Y., Simoneau, A. R., Liao, W. X., Yi, G., Hope, C., Liu, F., et al. (2009). WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Mol. Cancer Ther. 8, 458–468.
Wang, Z., Fukushima, H., Inuzuka, H., Wan, L., Liu, P., Gao, D., et al. (2012a). Skp2 is a promising therapeutic target in breast cancer. Front. Oncol. 1: 57. doi: 10. 3389/fonc. 2011. 00057
Wang, Z., Gao, D., Fukushima, H., Inuzuka, H., Liu, P., Wan, L., et al. (2012b). Skp2: a novel potential therapeutic target for prostate cancer. Biochim. Biophys. Acta 1825, 11–17.
